



# ABSTRACT CATEGORIES

The AACR Annual Meeting 2023 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2023. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is **November 17, 2022 (11:59 p.m. ET)** and the late-breaking and clinical trials abstract submission deadline is **January 12, 2023 (11:59 p.m. ET)**.

The abstract categories are listed in alphabetical order.

## **BCS Bioinformatics, Computational Biology, Systems Biology, and Convergent Science**

### **BCS01 Bioinformatics, Computational Biology, and Systems Biology** (See also MCB08: Genomics)

- Analytic pipeline optimization
- Application of bioinformatics to cancer biology
- Artificial intelligence and machine/deep learning
- Database resources
- Integrative computational approaches
- Molecular modeling
- New algorithms
- New software tools for data analysis
- Sequence analysis
- Statistical methods
- Systems engineering
- Whole cell modeling
- Other

### **BCS02 Convergent Science**

- Artificial intelligence and machine/deep learning
- Digital pathology
- Early detection and imaging
- Integration of clinical and research data
- Integrative cancer science
- Liquid biopsy: Multi-analyte and multi-omic
- Mathematical modeling
- Network biology and precision medicine
- Physical sciences in oncology
- Other

## **CH Chemistry**

### **CH01 Drug Discovery, Design, and Delivery**

- Basic and applied nanotechnology and therapeutics
- Chemoinformatics, in silico screening, and computational methods
- Drug delivery
- Drug design
- High-throughput screening (assays and libraries)
- Lead identification
- Lead optimization
- Nanotechnology drug delivery
- Natural products
- Synthesis, metabolism, and disposition
- Other

### **CH02 Proteomics and Mass Spectrometry**

- Biological mass spectrometry and systems biology
- Proteomics and biomarker discovery
- Proteomics and signaling networks
- Other

### **CH03 Structural and Chemical Biology**

- Chemical genetics and genomics
- Nanotechnology in chemical biology
- Small molecule, protein, and nucleic acid interactions
- Target identification, small molecule probes, and libraries
- X-ray and NMR structures
- Other

## ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:

**November 17, 2022 (11:59 p.m. ET)**

Late-Breaking and Clinical Trials Abstract

Submission Deadline: **January 12, 2023 (11:59 p.m. ET)**

### **CL Clinical Research**

(not including clinical trials, see also the Clinical Trials (CT) categories)

#### **CL01 Biomarkers**

Biomarkers predictive of therapeutic benefit  
Diagnostic biomarkers  
Early detection biomarkers  
Liquid biopsies: Circulating nucleic acids  
Liquid biopsies: Circulating tumor cells  
Metastasis biomarkers  
Prognostic biomarkers  
Spatial proteomics and transcriptomics  
Other

#### **CL02 Biostatistics in Clinical Trials**

Design and analysis of clinical trials  
New study designs: Theory, methodology, and modeling  
Statistical modeling for cancer studies  
Other

#### **CL03 Clinical Endocrinology**

(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)

Endocrine-related cancers  
Growth factors, receptors, and signal transduction  
Hormone receptors and diagnosis/prognosis  
Hormone signaling and inhibitors  
Hormone synthesis, metabolism, and inhibitors  
Neuroendocrine and other endocrine factors  
Nuclear receptors: Structure and function  
Preclinical studies of endocrine-related cancers  
Receptors and signal transduction  
Steroid hormone receptors  
Other

#### **CL04 Clinical Outcomes Research**

Clinical outcomes research

#### **CL05 Clinical Research in the Elderly**

Aging, immunity, and cancer  
Other

#### **CL06 Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations**

Biobanking/biospecimen collection  
Clinical trial design  
Community-engaged research/community-based participatory research  
Community outreach and patient accrual  
Impact of COVID-19 on patient accrual  
Other

#### **CL07 Immuno-oncology**

(See also ET01: Biological Therapeutic Agents; IM01: Preclinical Immunotherapy)

Adoptive cell therapy  
Combination immunotherapies  
Immune checkpoints  
Immune mechanisms invoked by other therapies including chemotherapy  
Immune mechanisms invoked by radiation therapy  
Immune monitoring/clinical correlates  
Immune response to therapies  
Immunomodulatory agents and interventions  
Inflammation, immunity, and cancer  
Modifiers of the tumor microenvironment  
Therapeutic antibodies, including engineered antibodies  
Vaccines (oncolytic and prophylactic)  
Other

#### **CL08 Pediatric Cancer – Clinical Investigations**

(See also CT09: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB06: Pediatric Cancer - Basic Science)

Adolescent and young adult oncology  
Childhood cancer drug development  
Immunotherapeutic approaches to pediatric cancer  
Pediatric cancer predisposition and surveillance  
Survivorship, late effects, and second cancers  
Therapeutic dosing, resistance, and combination therapy application  
Translational pediatric cancer research  
Other

#### **CL09 Precision Oncology**

Combination therapy  
Molecular targeted therapy  
Other

#### **CL10 Radiation Oncology**

(See TB07: Radiation Science; ET08: Preclinical Radiotherapeutics)  
Clinical radiotherapeutic studies  
Interventional radiology  
Modification of radiosensitivity  
Radiation-immunotherapy and other radiotherapeutic combinations  
Radiation-induced late effects/second cancers  
Radiation-induced resistance  
Other

#### **CL11 Real-World Data and Real-World Evidence**

Analyses using clinico-genomic databases  
Clinical informatics and data science  
Retrospective clinical analyses  
Other

#### **CL12 Surgical Oncology (including Prophylactic Surgery)**

Surgical oncology

#### **CL13 Survivorship Research and Supportive Care**

Biology of cell and tissue damage  
Cardio-oncology  
Comparative effectiveness research and cost-effective studies  
Late effects of cancer and its treatment, including second cancers  
Psycho-oncology  
Supportive care, palliation, and pain management  
Translational survivorship research  
Other

#### **CL14 Translational Research – Molecular Biology in Clinical Oncology**

(See also TB03: In Vivo Imaging)

Clinical imaging  
Clinical radionuclide theranostics  
Cytogenetics and clinical molecular genetics  
Epigenetic therapy  
Functional and molecular imaging  
Laboratory correlates for targeted agents  
Molecular classification of tumors  
Radiomics  
Tumor staging: Correlation of clinical and molecular markers  
Other

### **COVID COVID-19 and Cancer**

#### **COVID01 COVID-19 and Cancer**

Cancer drug repurposing to treat COVID-19  
Cancer prevention and early detection during the COVID-19 pandemic  
Clinical trials [See also CT02: COVID-19, Cancer, and Clinical Trials (Phase I–Phase IV and Trials in Progress)]  
Continuity of cancer care  
COVID-19 vaccines and immune responses among cancer patients  
Effects of cancer immunotherapies on patients with COVID-19 (with or without cancer)  
Effects of COVID-19 on cancer survivorship  
Epidemiology and registries of COVID-19 and cancer (including biorepositories)  
Health inequities and disparities during the COVID-19 pandemic  
Intersection of the biology of SARS-CoV-2 and cancer  
Risk factors and comorbidities resulting in adverse outcomes for cancer patients with COVID-19  
Other

## CT Clinical Trials

### CT01 Clinical Trials in Progress

Phase I clinical trials in progress  
Phase II clinical trials in progress  
Phase III clinical trials in progress

### CT02 COVID-19, Cancer, and Clinical Trials

(See also COVID01: COVID-19 and Cancer)

Clinical trials in progress

Phase I

Phase II

Phase III

Phase IV, observational, and expanded access

### CT03 First-in-Human Phase I Clinical Trials

First-in-human phase I clinical trials

### CT04 Phase I Adult Clinical Trials

(See also ET07: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

Phase I adult clinical trials

### CT05 Phase II Adult Clinical Trials

Phase II adult clinical trials

### CT06 Phase III Adult Clinical Trials

Phase III adult clinical trials

### CT07 Phase I, II, or III Clinical Trials in the Elderly

Phase I, II, or III clinical trials in the elderly

### CT08 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

Phase I, II, or III clinical trials in minorities and medically underserved populations

### CT09 Phase I, II, or III Clinical Trials in Pediatric Cancer

(See also CL08: Pediatric Cancer Clinical Investigations; TB06: Pediatric Cancer Basic Science)

Phase I, II, or III clinical trials in pediatric cancer

## EN Endocrinology

### EN01 Molecular, Preclinical, and Clinical Endocrinology

(See also CL03: Clinical Endocrinology)

Endocrine-related cancers

Growth factors, receptors, and signal transduction

Hormone receptors and diagnosis/prognosis

Hormone signaling and inhibitors  
Hormone synthesis, metabolism, and inhibitors

Neuroendocrine and other endocrine factors

Nuclear receptors: Structure and function

Preclinical studies of endocrine-related cancers

Receptors and signal transduction

Steroid hormone receptors

Other

## ET Experimental and Molecular Therapeutics

### ET01 Biological Therapeutic Agents

(See also CL07: Immuno-oncology; IM01: Preclinical Immunotherapy)

Antireceptors

Apoptosis: Therapeutic manipulation

Growth factor receptors and other surface antigens as targets for therapy

Oncogenes, tumor suppressor genes, and gene products as targets for therapy

Protein kinases and phosphatases as targets for therapy

Role of microenvironment in therapeutic response

Other

### ET02 Drug Discovery

Antibody technologies

Biochemical modulators of the therapeutic index

Combination chemotherapies

Differentiation therapy

New targets

Novel assay technology

Novel drug delivery systems

Targeting the tumor microenvironment in drug development

Other

## ET03 Drug Resistance

Drug resistance in molecular targeted therapies

Drug transport and metabolism

Novel mechanisms

Regulation of gene expression in drug resistance

Reversal of drug resistance

Other

## ET04 Gene and Vector-Based Therapy

Antisense molecules

Gene therapy and radiation studies

Immune modulators

Vector systems and targeting strategies

Other

## ET05 Mechanisms of Drug Action

Cell cycle mechanisms of anticancer drug action

Cellular responses to anticancer drugs

Role of the microenvironment in therapeutic response

Other

## ET06 Molecular Targets

Cell death pathways and treatment

DNA damage response

Identification of molecular targets

Modulation of DNA repair

Molecular classification of tumors

for diagnostics, prognostics, and therapeutic outcomes

New nonclinical models for targets

Other

## ET07 Pharmacology, Pharmacogenetics, and Pharmacogenomics

(See also CT04: Phase I Adult Clinical Trials)

Cellular pharmacology

Molecular pharmacology

Pharmacogenetics and therapeutic response

Pharmacogenomics

Pharmacokinetics and pharmacodynamics

Preclinical toxicology

Other

## ET08 Preclinical

**Radiotherapeutics** (See also

TB07: Radiation Science;

CL10: Radiation Oncology)

Interactions of new agents with radiation

Modification of radiosensitivity

Molecular targets of radiation response

Normal tissue/cellular stress responses to radiation

Radioprotectors and radiosensitizers

Radiotherapeutic combinations

Theranostics/radiotheranostics

Other

## ET09 Small Molecule Therapeutic Agents

DNA-reactive agents

Epigenetic targets

HDAC and methyltransferase inhibitors

Novel antitumor agents

Novel targets and pathways

PI3K/AKT inhibitors

Platinum complexes

Proteasome inhibitors

Topoisomerases

Tubulin agents

Tyrosine kinase and phosphatase inhibitors

Other

## IM Immunology

### IM01 Preclinical Immunotherapy

(See also CL07: Immuno-oncology; ET01: Biological Therapeutic Agents)

Adoptive cell therapy

Combination immunotherapies

Immune checkpoints

Immune mechanisms invoked by other therapies including chemotherapy

Immune mechanisms invoked by

radiation therapy

Immune monitoring/clinical correlates

Immune response to therapies

Immunomodulatory agents and interventions

Inflammation, immunity, and cancer

Modifiers of the tumor

microenvironment

Therapeutic antibodies, including engineered antibodies

Vaccines (oncolytic and prophylactic)

Other

# ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:

**November 17, 2022 (11:59 p.m. ET)**

Late-Breaking and Clinical Trials Abstract

Submission Deadline: **January 12, 2023 (11:59 p.m. ET)**

## **IM02 Tumor Immunobiology**

Adaptive immunity in tumors  
Epigenetic regulation of tumor immunity  
Inflammation and cancer: Metastasis  
Inflammation and cancer: Tumor initiation and progression  
Innate immunity to tumors  
Microbiome, inflammation, and cancer  
Novel animal models  
Oncogenic pathway-mediated regulation of inflammation and tumor immunity  
Tumor antigenicity/processing and presentation  
Tumor-induced immune suppression: Extrinsic factors  
Tumor-induced immune suppression: Intrinsic factors  
Other

## **MCB Molecular/Cellular Biology and Genetics**

### **MCB01 Cell Cycle**

CDKs and CDK inhibitors  
Cell cycle checkpoints  
Control of cell cycle progression  
Telomeres and telomerase  
Other

### **MCB02 Cell Death**

Apoptosis  
Autophagy  
Bcl-2 family proteins  
Caspases  
Effects on mitochondria/mitochondrial function  
Inhibitor of apoptosis (IAP) family proteins  
Necrosis and necroptosis  
Transcriptional control of apoptosis  
Other

### **MCB03 Cell Growth Signaling Pathways**

Cell signaling  
Cell-cell interactions  
Growth factors  
GTPases, their regulators, and effectors  
Kinases and phosphatases  
Receptors  
Tumor-stromal cell interactions  
Ubiquitin and ubiquitin-like proteins  
Other

### **MCB04 Cellular Stress Responses**

Hypoxia  
Oxidative stress  
Premature cellular aging  
Senescence  
Unfolded protein response  
Other

### **MCB05 DNA Damage and Repair**

Chromosomal structural alterations/translocations  
Genomic instability  
Homologous recombination  
Mechanisms of genomic alterations  
Radiation-induced DNA damage  
Other

### **MCB06 Epigenetics and Epigenomics**

Chromatin structure and function  
DNA methylation  
Epigenetic changes as molecular markers of cancer  
Epigenomics  
Gene silencing  
Histone modification  
Other

### **MCB07 Gene Regulation and Transcription Factors**

Chromatin structure and function  
Gene expression  
Mechanisms of transcription  
Oncogenic transcription factors  
Posttranscriptional and translational control  
Promoters and enhancers of transcription  
Protein-protein interactions in transcription factor function  
Regulation of transcription factor function  
Transcriptional control of cell differentiation  
Other

### **MCB08 Genomics** (See also BCS01: Bioinformatics, Computational Biology, and Systems Biology)

Functional genomics  
Genomic profiling of tumors  
High-throughput sequencing  
Large-scale approaches to cancer gene discovery  
Microarrays  
Other

### **MCB09 Metabolism and Cancer**

Metabolic pathways  
Metabolomics  
Mitochondrial function  
Signaling pathways that regulate metabolism  
Other

### **MCB10 microRNAs and Other Noncoding RNAs**

Epigenetic control of miRNA expression  
miRNA profiling in cancer  
miRNA regulation of cancer biology  
miRNA-based diagnostics  
miRNA-based therapeutics  
miRNAs as tumor suppressors/oncogenes  
Noncoding RNAs  
Other

### **MCB11 Oncogenes and Tumor Suppressor Genes**

Cytoplasmic signal transducers  
Genotype/phenotype correlations  
Nuclear oncoproteins and tumor suppressor genes  
Oncogene growth factors and their receptors  
Tumor suppressor genes  
Other

## **PS Population Sciences**

(Including Diversity, Equity, and Inclusion)

### **PS01 Population Sciences**

Aging as a risk factor  
Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects  
Biomarkers of prognosis  
Cancer disparities research  
Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends  
Diet, alcohol, tobacco use, and other lifestyle risk factors  
Environmental and occupational risk factors  
Familial and hereditary cancers  
Functional studies of genetic variants  
Gene-gene and gene-environment interactions  
Genome-wide association studies (GWAS)/post-GWAS

Health services and comparative effectiveness research  
Implementation science  
Infection and immune factors  
Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)  
Pathway and candidate gene studies of risk or prognosis  
Pharmacoepidemiology  
Preneoplastic and tumor markers  
Primary and secondary intervention studies  
Psychosocial and behavioral epidemiology  
Risk prediction models for incidence, prognosis, and/or mortality  
Screening and early detection  
Statistical and epidemiological methodology  
Survivorship research  
Other

## **PR Prevention, Early Detection, and Interception**

(Including Diversity, Equity, and Inclusion)

### **PR01 Clinical Prevention, Early Detection, and Interception**

Application of molecular pathology in clinical prevention  
Biomarkers and intervention studies  
Cancer disparities research  
Cancer surveillance and screening studies  
Chemoprevention clinical trials  
Genomics and proteomics in cancer risk and response assessment  
Infections and virus-related cancers  
Microbiome and prevention  
Obesity, diet, physical activity, and energy balance  
Prevention and treatment of premalignant lesions (intraepithelial neoplasia)  
Prevention of second cancers  
Quality of life/late effects/survivorship  
Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials  
Screening and early detection  
Other

## ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:

**November 17, 2022 (11:59 p.m. ET)**

Late-Breaking and Clinical Trials Abstract

Submission Deadline: **January 12, 2023 (11:59 p.m. ET)**

### **PR02 Preclinical Prevention, Early Detection, and Interception**

Animal models in prevention  
Behavioral sciences and prevention  
Biological and biochemical mechanisms in prevention  
Biomarkers and intervention studies  
Cancer communication and decision making  
Cellular models  
Chemoprevention studies  
Diet, nutrition, and cancer  
Microbiome and prevention  
Molecular markers in prevention research  
Molecular targets for prevention  
New agent development  
Screening and early detection  
Other

### **RSP Regulatory Science and Policy**

#### **RSP01 Regulatory Science and Policy**

Biosimilars and generics  
Clinical trial design and accrual  
Combination therapies and codevelopment of investigational agents and diagnostics  
Data science and informatics  
International regulatory issues  
Novel endpoints and biomarkers  
Real-world evidence and retrospective analyses  
Tobacco and e-cigarette regulation  
Other

### **SHP Science and Health Policy**

#### **SHP01 Science and Health Policy**

Cancer disparities  
Cancer survivorship  
Implementation science  
Patient advocacy and engagement  
Value and cost issues in cancer care  
Other

### **TB Tumor Biology**

#### **TB01 Angiogenesis**

Angiogenesis and angiogenesis inhibitors  
Host-tumor interactions  
Molecular mechanisms of angiogenesis  
Novel pro- and antiangiogenic factors  
Tumor microcirculation and the microenvironment  
Other

#### **TB02 Carcinogenesis**

Chemical, environmental, and virus-induced carcinogenesis  
Mutagenesis  
Other

#### **TB03 In Vivo Imaging** (See also CL14: Translational Research: Molecular Biology in Clinical Oncology)

Advanced nanotechnology and imaging  
Application of imaging technology to the clinic  
Imaging in animal models  
Imaging of molecular and cellular events in the tumor microenvironment  
Imaging of molecular and cellular events in tumors and tumor cells  
Imaging the immune response  
Imaging tumor metabolism  
New targets for imaging  
Other

#### **TB04 Metastasis**

Actin cytoskeleton  
Biomarkers of metastasis  
Epithelial/mesenchymal transition (EMT and MET)  
Expression profiling of tumor progression and metastasis  
Genes that regulate migration and invasion  
Imaging of tumor progression and metastasis  
Invasion and migration  
Metastasis-promoting genes  
Metastasis suppressor genes  
Premetastatic niche  
Therapeutic metastasis prevention  
Other

### **TB05 Nonclinical Models of Cancer**

3-D and tissue recombinant models  
Developmental phenotypes of cancer genes  
Human-in-mouse models of human cancer  
Model organisms in drug discovery  
Mouse models of human cancer  
Noninvasive imaging in animal models  
Organoids  
Other animal and cell models of cancer  
Patient-derived xenograft models  
Zebrafish models of cancer  
Other

#### **TB06 Pediatric Cancer - Basic Science** (See also CL08: Pediatric Cancer - Clinical Investigations; CT09: Phase I, II, or III Clinical Trials in Pediatric Cancer)

Developmental origins and drivers of pediatric cancer  
Pediatric cancer genomics and epigenomics  
Pediatric cancer models  
Pediatric cancer tumor microenvironment and tumor heterogeneity  
Other

#### **TB07 Radiation Science**

(See also CL10: Radiation Oncology; ET08: Preclinical Radiotherapeutics)  
Modulators of radiation response  
Photobiology/photodynamic therapy  
Radiation dose fractionation  
Radiation-activated signaling pathways  
Radiation-induced gene expression  
Radiation-induced resistance  
Radiobiology research  
Radioprotectors and radiosensitizers  
Other

#### **TB08 Stem Cell Biology**

Adult stem cells  
Cancer stem cells  
Developmental pathways in cancer  
Embryonic stem cells  
Stem cell markers  
Stem cells and regenerative medicine in oncology  
Other

### **TB09 Tumor Adhesion**

Cell adhesion and extracellular matrix  
Cell-cell adhesion  
Drug resistance  
Other

#### **TB10 Tumor Evolution and Heterogeneity**

Causes and consequences of tumor heterogeneity  
Clonal evolution  
Complex adaptive systems  
Methods to measure tumor evolution and heterogeneity  
Other

#### **TB11 Tumor Microenvironment**

Chemokines in the microenvironment  
Drug targets in the microenvironment  
Extracellular matrix and integrins  
Gene expression in the microenvironment  
Immune cells in the tumor microenvironment  
Inflammatory cells as regulators of tumor growth  
Microbiome  
Organ-specific microenvironments  
Proteases and inhibitors in the microenvironment  
Tumor dormancy  
Tumor/stromal interactions  
Tumor-immune system interactions  
Other